» Articles » PMID: 22505518

Kallikrein 6 is a Novel Molecular Trigger of Reactive Astrogliosis

Overview
Journal Biol Chem
Specialty Biochemistry
Date 2012 Apr 17
PMID 22505518
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Kallikrein-related peptidase 6 (KLK6) is a trypsin-like serine protease upregulated at sites of central nervous system (CNS) injury, including de novo expression by reactive astrocytes, yet its physiological actions are largely undefined. Taken with recent evidence that KLK6 activates G-protein-coupled protease-activated receptors (PARs), we hypothesized that injury-induced elevations in KLK6 contribute to the development of astrogliosis and that this occurs in a PAR-dependent fashion. Using primary murine astrocytes and the Neu7 astrocyte cell line, we show that KLK6 causes astrocytes to transform from an epitheliod to a stellate morphology and to secrete interleukin 6 (IL-6). By contrast, KLK6 reduced expression of glial fibrillary acidic protein (GFAP). The stellation-promoting activities of KLK6 were shown to be dependent on activation of the thrombin receptor, PAR1, as a PAR1-specific inhibitor, SCH79797, blocked KLK6-induced morphological changes. The ability of KLK6 to promote astrocyte stellation was also shown to be linked to activation of protein kinase C (PKC). These studies indicate that KLK6 is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis and that this is likely to occur at least in part by activation of the G-protein-coupled receptor, PAR1.

Citing Articles

Neuroinflammation and Post-Stroke Depression: Focus on the Microglia and Astrocytes.

Lu W, Wen J Aging Dis. 2024; .

PMID: 38421829 PMC: 11745440. DOI: 10.14336/AD.2024.0214-1.


Stroke Related Brain-Heart Crosstalk: Pathophysiology, Clinical Implications, and Underlying Mechanisms.

Fan X, Cao J, Li M, Zhang D, El-Battrawy I, Chen G Adv Sci (Weinh). 2024; 11(14):e2307698.

PMID: 38308187 PMC: 11005719. DOI: 10.1002/advs.202307698.


Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection.

Vicente-Acosta A, Ceprian M, Sobrino P, Pazos M, Loria F Front Pharmacol. 2022; 13:888222.

PMID: 35721207 PMC: 9199389. DOI: 10.3389/fphar.2022.888222.


Blocking Kallikrein 6 promotes developmental myelination.

Yoon H, Triplet E, Simon W, Choi C, Kleppe L, De Vita E Glia. 2021; 70(3):430-450.

PMID: 34626143 PMC: 8732303. DOI: 10.1002/glia.24100.


Hypoxia Inducible Factor-1α Attenuates Ischemic Brain Damage by Modulating Inflammatory Response and Glial Activity.

Amin N, Chen S, Ren Q, Tan X, Botchway B, Hu Z Cells. 2021; 10(6).

PMID: 34205911 PMC: 8229365. DOI: 10.3390/cells10061359.


References
1.
Poser C, Paty D, Scheinberg L, McDonald W, Davis F, Ebers G . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983; 13(3):227-31. DOI: 10.1002/ana.410130302. View

2.
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C . EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 2000; 402(6764):884-8. DOI: 10.1038/47260. View

3.
Fitch M, Silver J . CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp Neurol. 2007; 209(2):294-301. PMC: 2268907. DOI: 10.1016/j.expneurol.2007.05.014. View

4.
Seminario-Vidal L, Kreda S, Jones L, ONeal W, Trejo J, Boucher R . Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of rho- and Ca2+-dependent signaling pathways. J Biol Chem. 2009; 284(31):20638-48. PMC: 2742828. DOI: 10.1074/jbc.M109.004762. View

5.
Morcos Y, Lee S, Levin M . A role for hypertrophic astrocytes and astrocyte precursors in a case of rapidly progressive multiple sclerosis. Mult Scler. 2003; 9(4):332-41. DOI: 10.1191/1352458503ms931oa. View